SCHEMBL2965026

SCHEMBL2965026

Cc1ccc(-c2ccc(-c3ccccn3)cc2)cc1.Cc1ccc(-c2ccc(-c3ccccn3)cc2)cc1.Cc1ccc(-c2ccc(-c3ccccn3)cc2)cc1.[Ir]

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 5/20 0.56
PKM P14618 3/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
KDM4E B2RXH2 6/20 0.52
LMNA P02545 3/20 0.52
CYP1A2 P05177 2/20 0.52
CCR1 P32246 2/20 0.52
CCR5 P51681 2/20 0.52
CCR8 P51685 2/20 0.52
POLB P06746 1/20 0.52
METAP1 P53582 1/20 0.52
BLM P54132 1/20 0.52
HIF1A Q16665 1/20 0.52
DOHH Q9BU89 1/20 0.52
P4HTM Q9NXG6 1/20 0.52
CYP2D6 P10635 1/20 0.51
CYP19A1 P11511 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL346638 0.98 TP53 (0.57) TP53PKMMEN1KMT2AKDM4E
SCHEMBL30695837 0.98 TP53 (0.57) TP53PKMMEN1KMT2AKDM4E
SCHEMBL12339129 0.98 TP53 (0.57) TP53PKMMEN1KMT2AKDM4E
SCHEMBL1815589 0.98 TP53 (0.57) TP53PKMMEN1KMT2AKDM4E
SCHEMBL39128 0.96 TP53 (0.59) TP53PKMMEN1KMT2AKDM4E
SCHEMBL29577473 0.96 TP53 (0.59) TP53PKMMEN1KMT2AKDM4E
SCHEMBL17709412 0.94 TP53 (0.57) TP53PKMMEN1KMT2AKDM4E
Bromide SCHEMBL7055840 0.94 TP53 (0.57) TP53PKMMEN1KMT2AKDM4E
SCHEMBL17709413 0.94 TP53 (0.57) TP53PKMMEN1KMT2AKDM4E
SCHEMBL17709417 0.94 TP53 (0.57) TP53PKMMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772226-B2 Condensed imidazole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-10 US disclosed
US-20090018331-A1 CONDENSED IMIDAZOLE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-01-15 US disclosed
US-20060094722-A1 Combination drug EISAI CO., LTD. (JP) 2006-05-04 US disclosed
EP-1514552-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE Eisai Co., Ltd. (JP) 2005-03-16 EP disclosed
US-20040116328-A1 Condensed imidazole derivatives EISAI CO., LTD. (JP) 2004-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094722-A1 Combination drug DPP4, GLP1R, DPP7 TP53 4702/4885PKM 1861/4885MEN1 1858/4885
US-20090018331-A1 CONDENSED IMIDAZOLE DERIVATIVES DPP4, HDAC1, DPP7 TP53 2431/4885PKM 2652/4885MEN1 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.